CTS Corporation Earnings Call Highlights Broad-Based Strength

CTS Corporation ((CTS)) has held its Q1 earnings call. Read on for the main highlights of the call.

CTS Corporation’s latest earnings call delivered a notably upbeat tone, underscored by double‑digit revenue growth, expanding margins, and robust bookings across key end markets. Management balanced this optimism with clear acknowledgment of macro, cost, and policy headwinds, but the overarching message was one of disciplined execution and confidence in the diversified growth strategy.

Broad-Based Revenue Growth Supports Diversification Strategy

CTS reported Q1 sales of $139 million, up 11% year over year and 1% sequentially, underscoring traction in its diversification push. Diversified end markets led the way with sales up 18%, while transportation rose 3%, signaling that the portfolio is becoming less reliant on any single sector.

Medical Business Delivers Standout Performance

Medical sales hit $25 million, a sharp 28% increase from a year ago, making it one of the fastest-growing segments. Bookings climbed 18%, driving a healthy 1.2 book‑to‑bill, and CTS expects continued double‑digit growth as it expands capacity for therapeutic and aesthetics applications.

Industrial Segment Builds Momentum

Industrial sales reached $37 million, up 14% year over year, supported by recovering OEM and distribution channels. Bookings accelerated 28% with a book‑to‑bill of 1.29, reflecting wins in printing, flow meters, and temperature sensing and giving investors visibility into sustained industrial demand.

Transportation Remains Stable with New Program Wins

Transportation sales were $60 million, rising 3% year over year and 7% sequentially, signaling resilience despite softer light‑vehicle outlooks. CTS highlighted multiple new awards, including current sensing and foot controls in Europe and an accelerometer program with a North American OEM, strengthening its footwell and sensor portfolio.

Margin Expansion Highlights Operational Discipline

Adjusted gross margin improved to 39.5%, an increase of 250 basis points from last year and 40 basis points sequentially, driven by operational efficiencies and favorable mix. This expansion suggests CTS is not only growing the top line but also converting more of that growth into profit despite rising input costs.

Profitability Surges on Higher Margins

Adjusted diluted EPS rose to $0.62 from $0.44 a year ago, a roughly 41% increase, while GAAP diluted EPS climbed to $0.59 from $0.44. The strong earnings growth, outpacing revenue, underscores the leverage in the business model as CTS executes on efficiency and mix improvements.

Bookings Strength and Backlog Underpin Visibility

The company posted a solid company‑wide book‑to‑bill of 1.1, up about 4% versus last year, with particular strength in industrial and medical. Total booked business stood at approximately $1.1 billion at quarter‑end, providing multi‑year revenue visibility and supporting the more confident tone on future growth.

Defense Wins Add Long-Tail Opportunity

CTS secured a significant underwater hull penetrator program with a potential value of about $20 million spread over five years. The company also notched multiple naval sonar and RF filter wins and added two new RF filter customers, expanding its presence in higher‑value defense applications.

Solid Cash Generation and Shareholder Returns

Operating cash flow totaled $17 million year‑to‑date, supporting a cash balance of $91 million against $63 million of borrowings. Management returned $10 million to shareholders via dividends and buybacks, repurchasing roughly 177,000 shares and leaving $82 million available under its repurchase authorization.

Narrowed Full-Year Guidance Reflects Cautious Confidence

CTS narrowed its full‑year 2026 outlook to sales of $560–$580 million and adjusted EPS of $2.35–$2.45, assuming current market conditions persist and a tax rate of 21–23%. Management expects medical to maintain double‑digit growth, industrial to stay solid, transportation volumes to be slightly down overall with some H2 commercial vehicle improvement, and aerospace and defense bookings to normalize in the second half.

Aerospace & Defense Timing Creates Near-Term Softness

Aerospace and defense bookings declined year over year and posted a book‑to‑bill below one in Q1, largely due to the timing and lumpiness of government funding decisions. CTS expects these delays to ease and bookings to pick up in the second half, but near‑term visibility in the segment remains somewhat constrained.

Inflation and Supply Constraints Pose Cost Headwinds

Management flagged continued inflationary pressure from precious metals, oil‑linked materials such as resin and epoxy, and transportation costs, along with potential semiconductor and rare‑earth constraints. These headwinds are expected to weigh on results from late Q1 into Q2, and CTS is working closely with customers and suppliers to offset impacts through pricing and sourcing actions.

Macro and Geopolitical Risks Cloud H2 Transportation

The company cautioned that geopolitical conflicts and macro uncertainty could dampen second‑half demand, particularly in light vehicles. Industry forecasts point to softer global volumes, with North America around 15 million units, Europe at 16–17 million, and China near 32 million, implying modest pressure on transportation production.

Tariff Exposure and Policy Shifts Under Watch

CTS is monitoring potential changes to Section 232 tariffs on steel and aluminum, which could affect input costs and margins. Management emphasized its focus on agility and the ability to adjust pricing and sourcing with customers and suppliers to manage any margin impact from policy shifts.

Currency Tailwinds and Debt Dynamics May Normalize

Q1 sales benefited from approximately $3 million of favorable foreign exchange, and gross margin saw an estimated $0.7 million FX boost that may reverse in coming periods. Borrowings ticked up by roughly $5 million, tied to the timing of incentive payments, ongoing buybacks, and slightly higher capex, leaving cash generation positive but modest versus capital deployment.

In sum, CTS’s earnings call painted a picture of a company executing well on a diversification and margin‑expansion strategy, with medical and industrial leading growth and transportation holding steady. While cost inflation, FX, policy risks, and softer auto markets present challenges, strong bookings, a sizable backlog, and disciplined capital returns provide a supportive backdrop for investors tracking the story.